S1605, Phase II Trial of Atezolizumab in BCG-Unresponsive Non-Muscle Invasive Bladder Cancer (CTMS# 18-0014)
This phase II trial studies how well atezolizumab works in treating patients with non-muscle invasive bladder cancer that has come back (recurrent) and has not responded to treatment (refractory) with Bacillus Calmette-Guerin (BCG). Immunotherapy with monoclonal antibodies, such as atezolizumab, may help the body's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread.
Bladder Cancer Surgery
Bladder cancer treatment often includes surgery to remove a cancerous tumor. At Mays Cancer Center, home to UT Health San Antonio MD Anderson Cancer Center, our team regularly performs these complex procedures. Our skilled genitourinary surgeons treat a very high number of patients, giving our team exceptional expertise. Some bladder surgery affects your body’s ability to urinate. Our surgeons perform reconstructive procedures to restore function. Many patients can urinate on their own after surgery, even without a bladder.
S1602, A Phase III Randomized Trial to Evaluate the Influence of BCG Strain Differences and T Cell Priming with Intradermal BCG Before Intravesical Therapy for BCG-Naive High-Grade Non-Muscle Invasive Bladder Cancer (CTMS# 16-0138)
This randomized phase III trial studies Tokyo-172 strain bacillus Calmette-Guerin (BCG) solution with or without a vaccination using Tokyo-172 strain BCG to see how well it works compared with TICE BCG solution in treating patients with bladder cancer that has not spread to muscle. BCG is a non-infectious bacteria that when instilled into the bladder may stimulate the immune system to fight bladder cancer. Giving different versions of BCG with vaccine therapy may prevent bladder cancer from returning.
A031803, Phase II Trial of Intravesical Gemcitabine and MK-3475 (Pembrolizumab) in the Treatment of Patients with BCG-Unresponsive Non-Muscle Invasive Bladder Cancer CTMS#: 20-0004
This phase II trial studies the effect of adding pembrolizumab to gemcitabine in treating patients with non-muscle invasive bladder cancer whose cancer does not respond to Bacillus Calmette-Guerin (BCG) treatment. Chemotherapy drugs, such as gemcitabine, work in different ways to stop the growth of tumor cells, either by killing the cells, by stopping them from dividing, or by stopping them from spreading. Immunotherapy with monoclonal antibodies, such as pembrolizumab, may help the patient's immune system attack the cancer, and may interfere with the ability of tumor cells to grow and spread. Adding pembrolizumab to gemcitabine may delay the return of BCG-unresponsive bladder cancer for longer period compared to gemcitabine alone.
Bladder cancer is more advanced in South Texas, study finds
Bladder cancer is more aggressive and more advanced in South Texas residents than in many parts of the country, a study by the Mays Cancer Center indicates.
Rapamycin Prevents Surgery-Induced Immune Dysfunction in Patients with Bladder Cancer.
Finasteride Reduces Risk of Bladder Cancer in a Large Prospective Screening Study
Bladder cancer patients respond well to new immunotherapy tested at Mays Cancer Center
According to the study, 53.4% of participants receiving NF were free of cancer at three months and 45.5% of patients continued to be cancer-free for at least 12 months.